BioAtla (NASDAQ:BCAB) Given New $10.00 Price Target at HC Wainwright
BioAtla (NASDAQ:BCAB – Get Free Report) had its price objective lowered by stock analysts at HC Wainwright from $17.00 to $10.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 468.18% […]